picato
leo laboratories ltd. - ingenol mebutate - keratoosi, aktiininen - antibiootit ja chemotherapeutics for dermatological use, muut chemotherapeutics - picato on tarkoitettu ihon hoito ei‑liikasarveistusta, ei‑hypertrofisten aktiininen keratoosi aikuisilla.
heparin leo 100 iu/ml injektioneste, liuos
leo pharma a/s - heparin sodium - injektioneste, liuos - 100 iu/ml - hepariini
heparin leo 5000 iu/ml injektioneste, liuos
leo pharma a/s - heparin sodium - injektioneste, liuos - 5000 iu/ml - hepariini
heparin leo 25000 iu/ml injektioneste, liuos
leo pharma a/s - heparinum natricum - injektioneste, liuos - 25000 iu/ml - hepariini
protaminsulfat leo pharma 1400 anti-hepariini iu/ml injektio-/infuusioneste, liuos
leo pharma a/s - protamine sulfate - injektio-/infuusioneste, liuos - 1400 anti-hepariini iu/ml - protamiini
protopic
leo pharma a/s - takrolimuusi - dermatitis, atopic - muut dermatologiset valmisteet - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. esiintyy neljä kertaa tai useammin vuodessa), joka on ollut alustavan vastauksen enintään kuusi viikkoa, hoito kahdesti päivässä takrolimuusivoide (vauriot selvitetty, lähes selvitetty tai lievästi vaikuttaa).
kyntheum
leo pharma a/s - brodalumab - psoriasis - immunosuppressantit - kyntheum on tarkoitettu keskivaikean tai vaikean plakki psoriaasin hoitoon aikuispotilailla, jotka ovat systeemisessä hoidossa.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.
nexium control
glaxosmithkline dungarvan limited - esomepratsoli - gastroesofageaalinen refluksi - protonipumpun estäjät - nexium control on tarkoitettu lyhytkestoisen refluksi-oireiden hoitoon (esim. närästys ja hapon regurgitaatio) aikuisilla.
pursennid ex-lax 12 mg tabletti, päällystetty
haleon denmark aps - sennosides a+b, senna pods, alexandrian or tinnevelly, and leaf dry extract - tabletti, päällystetty - 12 mg - sennaglykosidit